The dengue vaccine developed by the Butantan Institute was 79.6% effective in clinical trials. According to the institution, follow-up with a group of 16,000 participants for two years has not yet recorded any serious cases of the disease among those who received the immunizer. The clinical study phase of the dengue vaccine began in 2016, with the administration of the vaccine to 10,000 volunteers aged between 2 and 59 years. Another 6,000 people received a placebo. The incidence of symptomatic dengue fever among participants was assessed from 28 days after immunization and continued for two years. The study will continue follow-up for five years and will end in 2024. The vaccine’s effectiveness was even higher among people who had contracted the disease before the study, reaching 89.2%. Among people who had never had contact with the virus, the effectiveness was 73.5%. The vaccine protects against the four serotypes of the dengue virus. However, during the research period, only types 1 and 2 were in circulation in Brazil. The effectiveness to avoid infection by these varieties was 89.5% and 69.6%, respectively. Adverse effects Among the more than 10,000 people immunized, only three people had adverse events considered serious up to 21 days after application of the vaccine, and all recovered completely. Years of research Butantan’s vaccine against dengue uses technology from the US National Institute of Health, licensed in 2009. The first phase of clinical trials was carried out in the United States, between 2010 and 2012, and the second part of the research, in Brazil, between 2013 and 2015. The tests showed that the vaccine is safe and protects against the four serotypes of the virus, which was one of the biggest difficulties for the development of an immunizer against the disease.
Agência Brasil
Folha Nobre - Desde 2013 - ©